5-alpha Reductase InhibitorsAzasteroidsCholestenone 5 alpha-ReductaseProstatic Hyperplasia3-Oxo-5-alpha-Steroid 4-DehydrogenaseDihydrotestosteroneAlopeciaEnzyme InhibitorsUrinary RetentionProstatePregnanoloneProstatic NeoplasmsAndrostenesFlutamideProstate-Specific AntigenHirsutismAndrogen AntagonistsHyaenidaeUrodynamicsTestosteroneDoxazosinOrchiectomyTosyl CompoundsHandling (Psychology)PregnatrienesPriapismL-Amino Acid OxidaseUrinationProstatectomyReceptors, AndrogenAnticarcinogenic AgentsConvulsantsAnilidesAdrenergic alpha-AntagonistsFadrozoleUrinary Bladder Neck ObstructionCentral Serous ChorioretinopathyAndrogensPrescriptionsDigital Rectal ExaminationReceptors, Tumor Necrosis Factor, Member 25Alopecia AreataProstatitisBias (Epidemiology)Erectile DysfunctionPentylenetetrazoleSilver StainingKeratin-5ChemopreventionOrgan SizeCentral Nervous System DepressantsManaged Care ProgramsBiopsy, NeedleTabletsAndrogen Receptor AntagonistsMesocricetusNucleolus Organizer Region17-alpha-HydroxyprogesteroneOxidoreductasesEstradiolNomogramsAdministration, CutaneousProgesteroneAndrostenedioneUrination DisordersDehydroepiandrosterone SulfateDouble-Blind MethodSteroidsReceptors, GABA-ABiopsySeizuresTreatment OutcomeSex Hormone-Binding GlobulinGlucuronidesClinical Trials, Phase III as TopicIncidenceSeverity of Illness IndexEthanolFinasteridePlacebosDose-Response Relationship, DrugNitrilesRandomized Controlled Trials as TopicRiskAntineoplastic Agents, HormonalRats, Sprague-DawleyAdministration, TopicalHealth Care CostsCost-Benefit AnalysisGelsSpermatogenesisFollow-Up StudiesConfounding Factors (Epidemiology)Drug InteractionsDrug Administration ScheduleArea Under CurveProbabilityDrug Therapy, CombinationData Interpretation, StatisticalModels, Statistical